ATC Group: D06AX09 Mupirocin

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of D06AX09 in the ATC hierarchy

Level Code Title
1 D Dermatologicals
2 D06 Antibiotics and chemotherapeutics for dermatological use
3 D06A Antibiotics for topical use
4 D06AX Other antibiotics for topical use
5 D06AX09 Mupirocin

Active ingredients in D06AX09

Active Ingredient Description
Mupirocin

Mupirocin is a novel antibiotic produced through fermentation by Pseudomonas fluorescens. Mupirocin inhibits isoleucyl transfer-RNA synthetase, thereby arresting bacterial protein synthesis. Mupirocin has bacteriostatic properties at minimum inhibitory concentrations and bactericidal properties at the higher concentrations reached when applied locally.

Related product monographs

Title Information Source Document Type  
BACTROBAN 2% Cream Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
BACTROBAN Nasal ointment Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
MURIPOCIN 2% w/w Ointment Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

Australia (AU)

Canada (CA)

Croatia (HR)

Cyprus (CY)

Estonia (EE)

Finland (FI)

France (FR)

Ireland (IE)

Israel (IL)

Japan (JP)

Malta (MT)

Mexico (MX)

New Zealand (NZ)

Nigeria (NG)

Poland (PL)

Spain (ES)

Tunisia (TN)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.